Preclinical research models for endometrial cancer: development and selection of animal models
- PMID: 39975595
- PMCID: PMC11835666
- DOI: 10.3389/fonc.2025.1512616
Preclinical research models for endometrial cancer: development and selection of animal models
Abstract
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, with rising incidence in recent years. Experimental animal models are crucial for studying the pathogenesis, advancing diagnostic methods, and developing new treatments. We review five main EC animal models. The use of spontaneous and chemically-induced models has decreased, with transgenic mouse and xenograft models becoming the most widely used. These models better simulate tumor molecular mechanisms and treatments, with the organoid-based patient-derived xenograft model (O-PDX) showing great promise in drug screening and personalized therapy. The application of humanized models remains limited due to technical challenges and high costs. In this review, we highlight the strengths and limitations of each model to guide researchers in their selection.
Keywords: animal model; endometrial cancer; humanized model; organoid; patient-derived xenograft model; preclinical research.
Copyright © 2025 Xue, Shi, Lun, Kan, Jia, Wu and Yang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool.Int J Mol Sci. 2022 Jun 3;23(11):6266. doi: 10.3390/ijms23116266. Int J Mol Sci. 2022. PMID: 35682944 Free PMC article.
-
Murine Xenograft Models as Preclinical Tools in Endometrial Cancer Research.Cancers (Basel). 2024 Nov 28;16(23):3994. doi: 10.3390/cancers16233994. Cancers (Basel). 2024. PMID: 39682182 Free PMC article. Review.
-
Organoid development and applications in gynecological cancers: the new stage of tumor treatment.J Nanobiotechnology. 2025 Jan 16;23(1):20. doi: 10.1186/s12951-024-03086-z. J Nanobiotechnology. 2025. PMID: 39819668 Free PMC article. Review.
-
Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.BMC Cancer. 2023 Dec 7;23(1):1205. doi: 10.1186/s12885-023-11434-9. BMC Cancer. 2023. PMID: 38062430 Free PMC article. Review.
-
Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis.Commun Med (Lond). 2021 Jul 30;1:20. doi: 10.1038/s43856-021-00019-x. eCollection 2021. Commun Med (Lond). 2021. PMID: 35602206 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources